Introduction {#s0005}
============

Coronaviruses (CoV) are divided into four genera, α and β CoV infect mammals, while γ and δ CoV tend to infect birds. There are six human-susceptible CoVs are reported till date. α-CoVs, HCoV-229E and HCoV-NL63, and β-CoVs, HCoV-HKU1 and HCoV-OC43 causes mild respiratory symptoms similar to a common cold. The other two known β-CoVs, SARS-CoV and MERS-CoV are responsible for severe and potentially fatal respiratory tract infections [@b0005], [@b0010], [@b0015].

Corona virus infectious disease 2019 (COVID-19), caused by novel corona virus, SARS-CoV-2 is an emerging infectious disease posing a serious threat to public health [@b0020]. SARS-CoV-2 is a ß-corona virus, first identified in Wuhan, China. Recently world health organisation (WHO) declared COVID-19 as a pandemic. As of 25 March 2020, there were nearly 18 440 deaths occurred worldwide due to COVID-19. However, there are no clinically approved vaccines or therapeutic agents are available for treating COVID-19 [@b0025], [@b0030]. Researchers, therefore, focused on discovery of novel anti-viral agents against this pandemic. However, high attrition rates, substantial costs and slow pace are the major limitations for discovery of new drugs against this emerging pandemic [@b0035] **.**

Drug repurposing/repositioning is a strategy of identifying newer therapeutic applications for existing clinically approved drugs [@b0040]. This can be an effective approach to accelerate drug discovery process against emerging pandemics like COVID-19. Niclosamide (NIC) is an FDA approved anthelmintic drug. Recent drug repurpose screening identified NIC as an antimetabolite, antibacterial and anticancer agent [@b0045], [@b0050] Compelling body of evidences also suggest NIC also possess broad spectrum antiviral properties including SARS-CoV (IC~50~ = 1.56 µM) [@b0055], [@b0060]. Recently, it was also reported that, NIC exhibited *in vitro* antiviral activity against SARS-CoV-2 (IC~50~ = 0.28 µM) [@b0065]. NIC, therefore, can therefore be a potential drug candidate for COVID-19. The plausible therapeutic mechanisms by which NIC acts as an antiviral agent against COVID-19 were presented in this work.

Plausible antiviral mechanisms of NIC against COVID-19 {#s0010}
======================================================

Spike (S) protein, 3C-like main protease, NTPase/helicase, RNA-dependent RNA polymerase (RNA replicase) and host receptors are the crucial drug targets of SARS-CoV-2 [@b0005], [@b0070]. The following pharmacological mechanisms may contribute to the antiviral propensity of NIC against COVID-19.i.NIC can block endocytosis of SARS-CoV-2

SARS-CoV-2 infects the permissive cells through the receptor of angiotensin converting enzyme-2 (ACE-2). Following receptor binding and induced conformational changes of S-protein, cathepsin L proteolysis occurs within endosomes for viral entry into host cells [@b0075], [@b0080].

NIC was reported to pH dependent endocytosis of human rhino virus (HRV) and influenza [@b0085]. This mechanism may also contribute to the antiviral effects of NIC against SAR-CoV-2. The ACE-2 inhibitory activity of NIC, however, need to be confirmed.ii.NIC can prevent autophagy of SARS-CoV-2 by inhibition of S-Phase kinase associated protein 2 (SKP2)

Recently it was reported that, NIC inhibited SKP2 and enhanced autophagy and reduced the replication of MERS-CoV replication [@b0090]. This can be the potential antiviral mechanism of NIC against SARS-CoV-2 ([Fig. 1](#f0005){ref-type="fig"} ).Fig. 1(a) Structure of SARS-CoV-2; (b) plausible mechanisms of NIC to control viral replication of COVID-19.

Conclusion {#s0015}
==========

Drug repurposing is an attractive approach for bringing new drugs quickly into market. Various drug repurposing screens identified NIC as a potential drug candidate against COVID-19. Prevention of viral entry by altering endosomal pH and prevention of viral replication by inhibition of autophagy are the plausible mechanisms of NIC against COVID-19. Clinical efficacy of NIC against COVID-19, therefore, need to be evaluated against COVID-19.
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